MFE-296

MSM Decreases Viability of EC Cells in A Dose-Dependent Manner

Methylsulfonylmethane (MSM), a low-toxicity dietary supplement, has demonstrated anti-inflammatory and anticancer properties in cancers. So far, the MSM might have a potentially beneficial effect in endometrial cancer (EC) treatment. Kowalska et al. assessed MSM's impact on EC cell (ISHIKAWA、MFE-296、MFE-280) viability, finding it reduced viability dose-dependently (Fig. 1a). The ISHIKAWA cell line, representing well-differentiated EC, showed the greatest sensitivity compared to MFE-296 and MFE-280. Viability significantly decreased in ISHIKAWA and MFE-296 at MSM doses below 600 mM. For MFE-280, a significant viability decrease occurred at 300 mM or higher. Therefore, 300 mM and 400 mM MSM concentrations were selected for further testing, with these doses exceeding the IC50 for ISHIKAWA (538.6 mM), MFE-296 (551.1 mM), and MFE-280 (380 mM), as determined by AlamarBlue assay. They re-evaluated EC cell viability by pre-treating with MSM before DOX to assess enhanced toxicity (Fig. 1b). Pre-treatment with MSM significantly reduced viability in ISHIKAWA and MFE-280 cells compared to DOX alone. In MFE-296, 400 mM MSM pre-treatment also significantly decreased viability. While no significant differences were found between MSM alone and MSM plus DOX treatments, cell viability decreased.

Fig. 1. Methylsulfonylmethane sensitizes endometrial cancer cells to doxorubicin (Kowalska K, Habrowska-Górczyńska D E, et al., 2021).

PMS2L2 Reduced the Viability of EA Cells Under 300 µM Carboplatin Treatment

LncRNA PMS2L2 plays critical protective roles in chondrocytes during lipopolysaccharide-induced inflammation. Zhang's team using deep sequencing revealed the altered expression of PMS2L2 in endometrial adenocarcinoma (EA) during chemotherapy. Then, they aim to investigate PMS2L2's functionality in modulating chemosensitivity and its impact on cell viability. PMS2L2 expression vectors and siRNAs were transfected into MFE-296 and TOV-112D cells. Transfection significantly altered PMS2L2 expression after 24 hours (Fig. 2A, p<0.05), confirming success. Post-transfection, cells were treated with 0 or 300 µM carboplatin for 24 hours, and viability was assessed via MTT assay. Carboplatin at 300 µM significantly reduced cell viability (Fig. 2B, p<0.05). PMS2L2 overexpression decreased EA cell viability, while its siRNA silencing increased viability only at 300 µM carboplatin (Fig. 2B, p<0.05).

Fig. 2. PMS2L2 improved the viability of EA cells under 300 µM carboplatin treatment (Zhang D, Sun X, et al., 2019).